In short
Regeneron Pharmaceuticals, Inc. (REGN) has revenue up 1.0% to $14.3B and net income up 2.1% to $4.5B year on year. Its net margin is 31.4%, and it trades at 20.0× trailing earnings. Fisclear found no medium- or high-severity risk flags in this filing. How we calculate this
Valuation
HealthcareLive · Yahoo FinancePrice
$920.69
$95.2B
15.2x
0.41%
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Sept 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.88%
Accommodative
10-Year Treasury
5.13%
2026-10-01
Unemployment
4.2%
Near full employment
CPI Index
336.3
2026-09-01
M2 Money Supply
$23.4T
2026-09-01
The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.
SWOT Analysis — REGN
Inflationary BoomStrengths
Operating Cash Flow: $5.0B (+12.6% YoY) — Operating cash flow grew 13% — the business generated more cash from day-to-day operations.
EPS (Diluted): $41.48 (+8.2% YoY) — Earnings per share rose 8% — each share earned more.
Total Assets: $40.6B (+7.4% YoY) — Total assets grew 7% — the company's resource base expanded.
Weaknesses
R&D spending is 41% of revenue — heavy investment in future growth, but also a drag on current profitability.
Opportunities
Net Income: $4.5B (+2.1% YoY) — Profit grew 2% — the company kept more of each dollar earned.
Revenue: $14.3B (+1.0% YoY) — Revenue grew 1% — the company sold more goods or services than the prior year.
Threats
No significant threats flagged.
Year-over-Year Changes
Operating Cash Flow
$5.0B
was $4.4B
Operating cash flow grew 13% — the business generated more cash from day-to-day operations.
EPS (Diluted)
$41.48
was $38.34
Earnings per share rose 8% — each share earned more.
Total Assets
$40.6B
was $37.8B
Total assets grew 7% — the company's resource base expanded.
Net Income
$4.5B
was $4.4B
Profit grew 2% — the company kept more of each dollar earned.
Revenue
$14.3B
was $14.2B
Revenue grew 1% — the company sold more goods or services than the prior year.
Risk Flags
0 high · 0 medium · 1 low- ○ Low
R&D spending is 41% of revenue — heavy investment in future growth, but also a drag on current profitability.
Technical Signals
Daily closes · 1-year dataRegeneron Pharmaceuticals, Inc.: common questions
Is Regeneron Pharmaceuticals, Inc. profitable?
Yes. Regeneron Pharmaceuticals, Inc. made a net profit of $4.5B in its latest fiscal year (fiscal 2025), a net margin of 31.4%.
Is Regeneron Pharmaceuticals, Inc.'s revenue growing?
Yes. Revenue grew 1.0% year on year, to $14.3B.
What is Regeneron Pharmaceuticals, Inc.'s P/E ratio?
Regeneron Pharmaceuticals, Inc. trades at 20.4× its trailing twelve-month earnings. In other words, the share price is about 20 times the profit per share the company earned over the past year.
Does Regeneron Pharmaceuticals, Inc. pay a dividend?
Yes. Regeneron Pharmaceuticals, Inc.'s forward dividend yield is 0.41%, the expected annual dividend as a share of the current share price.
Answers are generated from the figures in this report (updated 6 Nov 2026). Information, not investment advice.
Latest News
via FinnhubFiling History — REGN
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade REGN
Links open broker research pages. Not an endorsement or recommendation.
Research Regeneron Pharmaceuticals, Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.